Balazs Halmos, Professor of Medicine at Montefiore Health System, shared a post by NEJM on X, adding:
“Tour-de-force review by Drs. Hegedus/ Wirth/Tuttle on management of differentiated thyroid cancer– if you have time to read just 1 paper on DTC, this should be it!
Excellent nuancing of decisions at key steps beautifully illustrated by patient cases underlining the need for a dynamic risk-adapted approach- not infrequently supporting minimalistic decisions.
And love the closing quote:
‘When facts change, i change my mind- what do you do, Sir?’
Dogma as my friend Brendon Stiles says is just evidence that stopped evolving. Our patients cannot afford that!
Btw – when i saw Dr. Lori Wirth’s name on the paper i knew right away this will be Wirth reading!”
Quoting NEJM’s post:
A new review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. Read the Review Article “Management of Differentiated Thyroid Cancer” by Laszlo Hegedüs, MD, Lori J. Wirth, MD, and R. Michael Tuttle, MD: https://nej.md/4uBjgoZ Try asking AI Companion to break this article down into teaching points for you.
Title: Management of Differentiated Thyroid Cancer
Authors: Laszlo Hegedüs, Lori Wirth, R. Michael Tuttle
Read the Full Article.
